Task 13/C26 Challenge Models and Assays to Develop Influenza Vaccines

任务 13/C26 开发流感疫苗的挑战模型和检测

• 批准号: 7844063
• 负责人: JUDY BRITT
• 金额: $ 615.9万
• 依托单位: SOUTHERN RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-30 至 2012-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7844063
• 关键词: Task; 13; C26; Challenge; Models

The In Vitro and Animal Models for Emerging Diseases and Biodefense contract provides antimicrobial activity testing capabilities for Category A-C bacteria. Compounds demonstrating antimicrobial activity will receive further antimicrobial susceptibility testing against clinical panels of emerging and Category A-C bacterial pathogens. This contract also provides the development and standardization of small animal and non-human primate models, and may include efficacy testing of vaccines and/or therapeutics, including GLP studies to support product licensure. Vaccines and therapeutics which are efficacious in small animals may be further tested in non-human primate models.

新出现疾病和生物防御的体外和动物模型合同为A-C类细菌提供抗菌活性测试能力。显示抗菌活性的化合物将接受针对新出现的和A-C类细菌病原体的临床小组的进一步抗菌药敏感性测试。该合同还提供小动物和非人类灵长类动物模型的开发和标准化，并可能包括疫苗和/或疗法的有效性测试，包括支持产品许可的GLP研究。在小动物身上有效的疫苗和疗法可能会在非人类灵长类动物模型中进一步测试。